產品目錄 Home 主打產品 植物提取物 天然提取物 產品解決方案 聯繫我們 展會
藤茶提取物二氫楊梅素 Dihydromyricetin
楊梅素 Myricetin
木犀草素Luteolin
苦杏仁甙amygdalin
綠原酸Chlorogenic acid
芹菜素apigenin
厚朴提取物Magnolia bark extract
厚朴酚magnolol
和厚朴酚Honokiol
博落回提取物Macleaya cordata extract
血根碱sanguinarine
白屈菜紅碱Chelerythrine
迷迭香提取物rosemary leaf extract
迷迭香酸rosmarnic aicd
鼠尾草酸Carnosic acid
熊果酸Ursolic acid
鼠尾草酸油carnosic acid liquid oil
綠咖啡豆提取物green coffee bean extract
金銀花提取物honeysuckle flower extract
巴拿巴葉提取物Banaba leaf extract
枇杷葉提取物Loquat leaf extract
漆黃素Fisetin
虎杖甙Polydatin
芒果甙mangiferin
白樺脂醇Betulin
石杉碱甲huperzine a
阿魏酸Ferulic acid
白藜蘆醇Resveratrol

漆黃素Fisetin 

漆黃素

品名: 黃櫨提取物
形式: 粉末
外觀 : 黃色粉末
提取部位:葉

有效成分: 漆黃素

Cas號.:528-48-3

規格: 10%,20%,50%,98%

檢測方式HPLC

漆黃素

中文別稱:非瑟素,漆黃酸,紫鉚素,非瑟酮,3,3',4',7-四羥基黃酮

英文名稱:Fisetin

分 子 式:C15H10O6

分 子 量:286.24 

C A S號:528-48-3

純 度:HPLC≥5-98%漆黃素Fisetin

產品外觀:黃色針狀結晶

熔 點:320-325℃

儲存條件:2-8°C,乾燥、避光、密封 生產企業:長沙上禾生物

溶 解 性:溶于乙醇、丙酮和醋酸。幾乎不溶于水、 、苯、氯仿及石油醚。

提取來源:漆樹科植物木臘樹Rhus succedanea L

藥理藥效:抑制前列腺素、.酶抑制、解痙 

漆黃素Fisetin規格:5-98%

以上資料 由長沙上禾生物整理 產品詳詢:13657416805

漆黃素檢測方式:

 

漆黃素(fisetin)檢測方法

 

一、色譜條件

色譜柱:Inertsil ODS-3 4.6×150mm  5μm

流動相:乙腈∶水∶磷酸(23∶77∶0.1,V/V)

檢測波長:368nm

靈敏度:0.01AUFS

流速:1mL/min

進樣量:10μL

柱溫:25℃

 

二、溶液制備

  • 對照品溶液制備  精密稱取漆黃素對照品約3mg于25mL容量瓶中,用甲醇溶解定容。
  • 樣品溶液制備  精密稱取樣品(含量約10%)50mg于50mL容量瓶中,加約30mL甲醇,超聲振盪溶解30min,冷卻至室溫,用甲醇定容,以0.45μm微孔濾膜過濾,即得。

三、樣品測定

    在上述色譜條件下,待儀器穩定,基線平穩后,進樣測定,漆黃素保留時間約為20min,含量按外標法計算。

參考文獻:

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

  2. 2.

    Li W, Cai JH, Zhang J, Tang YX, Wan L. Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Int J Mol Sci. 2012;13:9741–53.

  3. 3.

    Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011;10:255–68.

  4. 4.

    Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis. 2009;30:300–7.

  5. 5.

    Li Z, Guo X, Guan J. An oxygen release system to augment cardiac progenitor cell survival and differentiation under hypoxic condition. Biomaterials. 2012;33:5914–23.

  6. 6.

    Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, Yu SH, Tsai YJ, Chiu SJ. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys. 2010;77:1527–35.

  7. 7.

    Ying TH, Yang SF, Tsai SJ, Hsieh SC, Huang YC, Bau DT, Hsieh YH. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8−/caspase-3-dependent pathway. Arch Toxicol. 2012;86:263–73. 

  8. 8.

    Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006;47:3164–77.

  9. 9.

    Crozier A, Burns J, Aziz AA, Stewart AJ, Rabiasz HS, Jenkins GI, Edwards CA, Lean ME. Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. Biol Res. 2000;33:79–88.

  10. 10.

    Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Suemura M, Kawase I, Tanaka T. Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol. 2003;111:1299–306.

  11. 11.

    Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, Yang LL. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol. 2002;76:351–9. 

  12. 12.

    Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9:68–76.

  13. 13.

    Haddad AQ, Fleshner N, Nelson C, Saour B, Musquera M, Venkateswaran V, Klotz L. Antiproliferative mechanisms of the flavonoids 2,2′-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer. 2010;62:668–81.

  14. 14.

    Chien CS, Shen KH, Huang JS, Ko SC, Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem. 2010;333:169–80.

  15. 15.

    Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis. 2010;31:1424–33. 

  16. 16.

    Touil YS, Auzeil N, Boulinguez F, Saighi H, Regazzetti A, Scherman D, Chabot GG. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochem Pharmacol. 2011;82:1731–9.

  17. 17.

    Ansó E, Zuazo A, Irigoyen M, Urdaci MC, Rouzaut A, Martínez-Irujo JJ. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol. 2010;79:1600–9.

  18. 18.

    Wu MY, Hung SK, Fu SL. Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity. J Agric Food Chem. 2011;59:10496–504.

  19. 19.

    Kim JY, Jeon YK, Jeon W, Nam MJ. Fisetin induces apoptosis in Huh-7 cells via downregulation of BIRC8 and Bcl2L2. Food Chem Toxicol. 2010;48:2259–64.

  20. 20.

    Chen Y, Wu Q, Song L, He T, Li Y, Li L, Su W, Liu L, Qian Z, Gong C. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl Mater Interfaces. 2015;7:534–42.

  21. 21.

    Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J. Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer. Mol Cancer Ther. 2017. 

  22. 22.

    Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, Ghaem-Maghami S, Aboagye EO. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016 Feb;18:1227–46.

  23. 23.

    Echarri GMJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when. Oncology (Williston Park). 2011;25:156–65. 170

  24. 24.

    Li QQ, Lee RX, Liang H, Zhong Y, Reed E. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 2013;30:424.

  25. 25.

    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

  26. 26.

    Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008;68:8555–63.

  27. 27.

    Kozics K, Valovicova Z, Slamenova D. Structure of flavonoids influences the degree inhibition of benzo(a)pyrene - induced DNA damage and micronuclei in HepG2 cells. Neoplasma. 2011;58:516–24. 

  28. 28.

    Katalinić M, Rusak G, Domaćinović BJ, Sinko G, Jelić D, Antolović R, Kovarik Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2010;45:186–92. 

  29. 29.

    López-Lázaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res. 2010;696:41–7.

  30. 30.

    Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, Tian B. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2011;108:84–93.

  31. 31.

    Khan N, Afaq F, Khusro FH, Mustafa AV, Suh Y, Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer. 2012;130:1695–705.


產品目錄  |  Home  |  主打產品  |  植物提取物  |  天然提取物  |  產品解決方案  |  聯繫我們  |  展會  |  網站地圖  |  手機版
  English     简体版     繁體版
網站首頁聯繫我們網站地圖